ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label ...
Restraint may be a modifiable risk factor, but more robust estimates of baseline risk are needed Hospital associated venous thromboembolism (VTE), defined as pulmonary embolism and deep vein ...
The global rise in anticoagulant use has increased the number of major bleeding events that warrant timely and effective pharmacologic reversal. Reversal strategies should be informed by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results